Transition to Cardiac Rehabilitation (T2CR) to Address Barriers of Multimorbidity and Frailty

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorVA Office of Research and Development

About this trial

Cardiac rehabilitation (CR) is a secondary prevention program for patients with cardiovascular disease (CVD). It is especially valuable as CVD increasingly occurs in combination with comorbidity, frailty, and complexities of care that predispose patients to functional decline, disability, and high costs. Still, few Veterans participate in CR, in part because of the difficult logistics to attend. Promising Practice home-based CR (HBCR) was developed to increase CR participation, but many Veterans remain too limited by comorbidity and frailty for participation. A Transition to CR (T2CR) intervention is a face-to-face program that fosters vital skills, education, insights, motivation, and patient-provider relationships conducive to successful HBCR thereafter. This study compares Veterans eligible for CR who are randomized to T2CR intervention versus usual care. Differences in functional capacity, HBCR participation, and healthy days at home are compared over one year. Patients' experiences and providers' perspectives of barriers and facilitators to T2CR are also compared.

Eligibility criteria

Qualifiers

ischemic heart disease (acute myocardial infarction or stable ischemia)

revascularization (coronary artery bypass grafting or percutaneous coronary intervention)

valvular heart disease (surgical or percutaneous intervention for mitral regurgitation or aortic stenosis)

or heart failure (with reduced or preserved ejection fraction)

Disqualifiers

Veterans with unstable medical condition as indicated by history, physical exam, and/or laboratory findings end-stage disease likely to be fatal within 12 months

severe cognitive impairment (MiniCog score 0-2)

history of addictive or behavioral issues that confound safe administration of HBCR

hearing loss that interferes with participation in the trial

Trial design

Treatments tested in this trial

  • T2CR Intervention
  • Usual Care

Treatment groups

250 Participants
are divided into 2 treatment groups